Literature DB >> 11819579

Tumoricidal activation of murine resident peritoneal macrophages on pancreaticcarcinoma by interleukin-2 and monoclonal antibodies.

Qi-Kui Chen, Shi-Zhen Yuan, Zhi-Yong Zeng, Zhi-Qing Huang.   

Abstract

Entities:  

Year:  2000        PMID： 11819579      PMCID： PMC4723507          DOI： 10.3748/wjg.v6.i2.287

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  11 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

Review 2.  Chemotherapy of adenocarcinoma of the pancreas.

Authors:  S F Schnall; J S Macdonald
Journal:  Semin Oncol       Date:  1996-04       Impact factor: 4.929

3.  Generation and application of monoclonal antibody to human pancreatic carcinoma.

Authors:  S Yuan; H Zhang; Q Chen
Journal:  Hybridoma       Date:  1996-08

4.  [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].

Authors:  Q K Chen; S Z Yuan
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1994-09

5.  Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha.

Authors:  S Verstovsek; D Maccubbin; M J Ehrke; E Mihich
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

Authors:  Q Chen; S Yuan
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.

Authors:  E Shiloni; A Eisenthal; D Sachs; S A Rosenberg
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

9.  Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.

Authors:  K Hori; E Mihich; M J Ehrke
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

10.  Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.

Authors:  I Kawase; K Komuta; H Hara; T Inoue; S Hosoe; T Ikeda; T Shirasaka; S Yokota; Y Tanio; T Masuno
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701
View more
  1 in total

1.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.